MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Women with axial spondyloarthritis are less likely than men to respond to multiple different classes of advanced therapies, ...

Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

IL-17A and IL-17F affect the pathogenesis of Crohn's disease and ulcerative colitis, although their precise role in the development of these disorders requires further characterization.

“Bimekizumab is launching extremely well as IL-17A/F has emerged as superior to IL-17A inhibition in several important indications. Uniquely, we could have the best targeting approaches for both ...

Belgian drugmaker UCB (Euronext: UCB) today announced new three-year data from Phase III trials, and their open-label ...

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...